Suraksha Diagnostic Ltd

Stage 2 · Advancing · week 7Setup 5.0 ★ FairSolid +5.6

As of 16 Oct 2026, Suraksha Diagnostic is in Stage 2 — advancing, the uptrend phase, in week 7 (since 1 Sep 2026). It closed at ₹307, 13.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. More about the company

₹306.7
-0.31% today
₹1,597 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dHospitals & Diagnostic Centres 19.4%-19.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.0 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #3 of 6 in Hospitals & Diagnostic Centres · #25 of 70 in Health Care

Is SURAKSHA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-13.8%
₹228 lo₹356 hi
13.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 7
1w13w26w
Week 7 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
7.8%
200 DMA: ₹284.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.11x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -2.2% vs MA50 +10.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.2%
3M
+18.4%
6M
+8.8%
YTD
+11.3%
1Y
+3.6%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #48 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
19.4%
20d Δ
-19.4pp
1M return
-10.4%
3M return
-12.2%
Industry Stage-2 % · last 20 days
Ranks #4 of 5 Stage 2 stocks in this industry.
Stage Cycle Timeline2024-12-06 → 2026-10-16
S? 42w
S4 22w
S1 10w
2024-12-062026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 6w → S2 4w → S4 22w → S1 10w → S4 6w → S1 1w → S2 7w current
Total tracked: 97 weeks across 8 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Breakout Watch
Latest: 2026-09-01
27 appearances in last 60 days. First seen: 2025-11-06.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 7 · Vol 0.11x
2026-10-15S2
Wk 7 · Vol 0.15x
2026-10-14S2
Wk 6 · Vol 0.19x
2026-10-13S2
Wk 6 · Vol 0.19x
2026-10-12S2
Wk 6 · Vol 0.24x
2026-10-09S2
Wk 6 · Vol 0.14x
2026-10-08S2
Wk 6 · Vol 0.32x
2026-10-07S2
Wk 5 · Vol 0.21x
2026-10-06S2
Wk 5 · Vol 0.29x
2026-10-05S2
Wk 5 · Vol 0.34x
2026-10-01S2
Wk 5 · Vol 0.46x
2026-09-30S2
Wk 5 · Vol 0.59x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹322.6
200 DMA
₹284.6
52W High
₹356
52W Low
₹228
5D Low
₹306.7
Resistance levels (recent highs)
20d High
₹356
60d High
₹356
120d High
₹356
250d High
₹356
Next resistance
+16.1%
to 20d High
Ask the Market AI about SURAKSHAAsk →
P/E (TTM)
46.3
Forward 31.5
Earnings Growth (YoY)
-5.4%
Revenue +31.2%
ROE
+13.8%
Profit margin +10.4%
Dividend Yield
0.17%
P/B 6.5
About this companyHealth Care· Hospitals & Diagnostic Centres

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.